Anticoagulant Clinical Trial
Official title:
Clinical, Biological and Genetic Determinants of Oral Anticoagulants' Activity
The primary objective of the present study is to determine the clinical, biological and
genetic determinants of the anticoagulant activity in patients treated with either anti-IIa
or anti Xa oral anticoagulants.
The secondary objective is to determine the clinical, biological or genetic determinants of
hemorrhagic or thrombotic complications during a one year follow-up.
Results will lead to a better prediction of both drug response and risk of complications.
Direct oral anticoagulants are changing clinical practices but a better knowledge of factors
that may predict both drug response and risk of complications is need.
Anticoagulant activity is influenced by different factors. Because the biological activity is
not easy to measure everywhere, it is important to clearly determine factors that are
involved.
A cohort of 550 patients that receive either an anti-IIa or an anti-Xa will be recruited.
The primary objective is to determine clinical, biological and genetic determinants of
anticoagulant activity.
This objective will be assessed through a multivariate logistic regression (separately for
anti-IIa and anti-Xa) with anticoagulant activity as dependent variable.
Variables that will be included in the statistical model are those known or measured at the
entry in the cohort such as :
- Clinical factors : age, sex, weight, dosage and time of the last dose
- Biological factors : serum creatinine level, plasma concentration of the drug
- Genetic polymorphisms :
Factor II and CES1 for anti-IIa drugs Factor X, CYP3, CYP3A4, CYP3A5 and ABCG2 for anti-Xa
drugs.
By using the same statistical approach and the same variables, predictive factors of either
hemorrhagic or thrombotic events will also be evaluated on the whole cohort. The occurence of
hemorrhagic and thrombotic complications will then be assessed through a phone call every 3
months during a one-year follow-up.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04010955 -
Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON)
|
||
| Recruiting |
NCT04673695 -
A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344
|
Phase 1 | |
| Completed |
NCT03893591 -
A Prospective Study to Examine the Need to Adjust the Dose of Apixaban When Used in Atrial Fibrillation and Obesity
|
||
| Completed |
NCT03895502 -
Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study
|
Phase 4 | |
| Completed |
NCT03154489 -
Effectiveness of a Multidisciplinary Medication Review With Follow-up for Patients Treated With Coumarin Anticoagulants in Primary Care
|
N/A | |
| Completed |
NCT04305821 -
Medico-economic Interest of the Protein S100b in Mild Head Trauma Under Anti-thrombotics
|
||
| Recruiting |
NCT06020560 -
Study of Low Molecular Weight Heparins
|
Phase 4 | |
| Not yet recruiting |
NCT05788900 -
Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Intravenous Administration
|
Phase 1 | |
| Not yet recruiting |
NCT05788913 -
Evaluation of the Pharmacodynamics of a Heparin With Its Biological Comparator, Subcutaneous Administration
|
Phase 1 | |
| Not yet recruiting |
NCT04592822 -
A Single Dose Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition
|
Phase 1 | |
| Recruiting |
NCT03772457 -
Predictive Value of Infarction Volume on Hemorrhagic Transformation in Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban
|
||
| Completed |
NCT03323320 -
Evaluation of Patient's Knowledge of Their NACO Treatment
|
N/A | |
| Recruiting |
NCT04257487 -
Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)
|
Phase 3 | |
| Completed |
NCT04272723 -
Management of Venous Thromboembolism in France: a National Survey Among Vascular Medicine Physicians
|
||
| Recruiting |
NCT04867200 -
A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344 in Healthy Volunteers
|
Phase 1 |